HCW Biologics Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

HCWB$1.02-1.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance sheets

Condensed Balance Sheets

	December 31,	June 30,
	2023	2024
Unaudited
ASSETS
Current assets:
Cash and cash equivalents	$3,595,101	$1,161,314
Accounts receivable, net	1,535,757	654,973
Prepaid expenses	1,042,413	404,918
Other current assets	230,916	164,607
Total current assets	6,404,187	2,385,812
Investments	1,599,751	1,599,751
Property, plant and equipment, net	20,453,184	22,806,052
Other assets	56,538	28,476
Total assets	$28,513,660	$26,820,091
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Liabilities
Current liabilities:
Accounts payable	$6,167,223	$16,877,463
Accrued liabilities and other current liabilities	2,580,402	6,341,676
Total current liabilities	8,747,625	23,219,139
Debt, net	6,304,318	9,900,721
Total liabilities	15,051,943	33,119,860
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):
Common stock:
Common, $0.0001 par value; 250,000,000 shares authorized and 36,025,104 shares issued at December 31, 2023; 250,000,000 shares authorized and 37,823,394 shares issued at June 30, 2024	3,603	3,782
Additional paid-in capital	83,990,437	86,977,024
Accumulated deficit	(70,532,323)	(93,280,575)
Total stockholders’ equity (deficit)	13,461,717	(6,299,769)
Total liabilities and stockholders’ equity (deficit)	$28,513,660	$26,820,091

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.